What is CONMED Corporation's stock symbol?
CONMED Corporation trades on the NASDAQ under the ticker symbol "CNMD."
How often does CONMED Corporation pay dividends? What is the dividend yield for CONMED Corporation?
CONMED Corporation declared a quarterly dividend on Monday, November 21st. Stockholders of record on Thursday, December 15th will be given a dividend of $0.20 per share on Thursday, January 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date of this dividend is Tuesday, December 13th.
Where is CONMED Corporation's stock going? Where will CONMED Corporation's stock price be in 2017?
2 brokerages have issued 1 year price targets for CONMED Corporation's stock. Their forecasts range from $43.00 to $48.00. On average, they expect CONMED Corporation's stock price to reach $45.50 in the next year.
When will CONMED Corporation announce their earnings?
CONMED Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What are analysts saying about CONMED Corporation stock?
Here are some recent quotes from research analysts about CONMED Corporation stock:
Needham & Company LLC analysts commented, "CNMD’s 4Q16 revenue beat and EPS missed consensus and management’s revenue and EPS guidance were below consensus due partly to an increased currency headwind. Positives include SurgiQuest sales which beat our estimate ($20M vs. $19M) and strong international growth while negatives included double-digit declines in domestic Orthopedic Surgery and Surgical Visualization which caused overall organic growth to slow from 3Q16." (2/2/2017)
According to Zacks Investment Research, "Over the past six months CONMED Corporation has outperformed the broader industry trends in terms of price performance. However, a falling estimate revision trend for the next year indicates looming concerns ahead. Foreign exchange movements have been unfavorably impacting the company’s results of late. Additionally, CONMED operates in a highly competitive environment which is likely to mar the top-line growth. Declining Orthopaedic surgery sales, especially in the U.S. in the last reported quarter is an added concern. Meanwhile, the company reported impressive third-quarter 2016 results wherein revenues surpassed the Zacks Consensus Estimate and increased on a year-over-year basis. The earnings were in-line with the estimate mark." (12/19/2016)
Leerink Swann analysts commented, "We remain cautious on the company’s ability to manage through what we believe could be meaningful top-line headwinds in F2H17 and FY2018 in order to return to and sustain a solid mid- single-digit growth trajectory after just 3% growth in F2Q17, including: (1) A competitive CRM (cardiac rhythm management) product cycle, (2) Current and upcoming competitive launches in DES (drug eluting stents), (3) Potential modest share loss in U.S. TAVR (transcatheter aortic valve replacement) with a competitor recently receiving an expanded indication that is likely ~12-18 months ahead of MDT only partially offset by MDT’s recent large valve size launch; and (4) Continued share loss in Neuromodulation, particularly in SCS (spinal cord stimulation), DBS (deep brain stimulation), and implantable drug infusion pumps." (11/23/2016)
Who owns CONMED Corporation stock?
CONMED Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (8.44%), Champlain Investment Partners LLC (5.33%), State Street Corp (2.27%), William Blair Investment Management LLC (1.57%), Westwood Holdings Group Inc. (0.90%) and Netols Asset Management Inc. (0.59%). Company insiders that own CONMED Corporation stock include Charles Farkas, Daniel Jonas, David M Bronson, Jerome J Lande, Jo Ann Golden, John L Workman, Luke A Pomilio, Mark D Snyder, Pat Beyer and Stephen Mandia.
Who sold CONMED Corporation stock? Who is selling CONMED Corporation stock?
CONMED Corporation's stock was sold by a variety of institutional investors in the last quarter, including Westwood Holdings Group Inc., Folger Hill Asset Management LP, Champlain Investment Partners LLC, GSA Capital Partners LLP, Dimensional Fund Advisors LP, Continental Advisors LLC, AQR Capital Management LLC and William Blair Investment Management LLC. Company insiders that have sold CONMED Corporation stock in the last year include Daniel Jonas, Luke A Pomilio and Mark D Snyder.
Who bought CONMED Corporation stock? Who is buying CONMED Corporation stock?
CONMED Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State Street Corp, Netols Asset Management Inc., Zebra Capital Management LLC, Dynamic Technology Lab Private Ltd, Bayesian Capital Management LP, Keybank National Association OH and Comerica Bank. Company insiders that have bought CONMED Corporation stock in the last two years include Charles Farkas, David M Bronson, John L Workman and Pat Beyer.
How do I buy CONMED Corporation stock?
Shares of CONMED Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CONMED Corporation stock cost?
One share of CONMED Corporation stock can currently be purchased for approximately $43.50.